An Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35months
Latest Information Update: 27 Dec 2024
At a glance
- Drugs Influenza-virus-vaccine-quadrivalent-Sinovac-Biotech (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sinovac Biotech
Most Recent Events
- 24 Dec 2024 Status changed from recruiting to completed.
- 24 May 2024 Planned primary completion date changed from 31 Dec 2023 to 31 May 2024.
- 29 Sep 2023 Status changed from not yet recruiting to recruiting.